B cell

Frost & Sullivan Co-Published Recombinant Type XVII Collagen Whitepaper with Trautec

Retrieved on: 
Thursday, January 25, 2024

Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.

Key Points: 
  • Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.
  • (To read the Recombinant Type XVII Collagen Whitepaper, go here: https://hub.frost.com/recombinant-type-xvii-collagen/ .)
  • In the process of skin wound repair, type XVII collagen plays a vital role by influencing the migration, proliferation, and differentiation of stem cells.
  • Recombinant Type XVII Collagen Whitepaper highlights the following:
    Recombinant Type XVII Collagen's Biological Functionality(safety, cell adhesion, anti-wrinkle effect, anti-hair loss effect, etc.

FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Cell Therapy Candidate

Retrieved on: 
Tuesday, January 23, 2024

an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.

Key Points: 
  • an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.
  • BlueRock Therapeutics, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, exercised its option to exclusively license OpCT-001, an iPSC-derived photoreceptor cell therapy for human retinal diseases.
  • Following the option exercise by BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics received an undisclosed license fee and are eligible to receive payments upon achievement of certain development and commercial milestones.
  • OpCT-001 is the first iPSC therapy candidate to be licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.

Diabetes Canada awards over $6 million in funding to new research projects

Retrieved on: 
Monday, January 22, 2024

Each research project receives a $100,000 grant annually for three years for a total of $6.2 million in funds committed by Diabetes Canada for the research community.

Key Points: 
  • Each research project receives a $100,000 grant annually for three years for a total of $6.2 million in funds committed by Diabetes Canada for the research community.
  • “To achieve our vision of a world free of the effects of diabetes, Diabetes Canada knows that it needs to harness the transformative and combined power of technological, medical, and scientific research,” says Laura Syron, President and CEO of Diabetes Canada.
  • The winning research projects for this year’s Diabetes Canada’s End Diabetes Awards were rigorously evaluated by scientists with expertise in diabetes research, with input from people with lived experience, and Diabetes Canada’s National Research Council.
  • For almost 50 years, Diabetes Canada has proudly supported outstanding diabetes research in Canada, administering more than $160 million in research grants, awards and partnerships to scientists and clinicians who have dedicated their careers to the fight against diabetes.

Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies

Retrieved on: 
Thursday, January 25, 2024

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.
  • The data being presented support the utility of engineered B cell medicines (BCMs) across a broad range of applications.
  • “Gene and cell therapies have transformative potential to treat previously intractable diseases, but have barriers to adoption such as lack of durability, inability to re-dose, and requirement of preconditioning for engraftment.
  • Our BCM platform has the potential to address these barriers,” said Richard A. Morgan, Ph.D., Chief Scientific Officer, Be Bio.

iXCells Biotechnologies Strengthens Leadership Team; Welcomes New CEO

Retrieved on: 
Thursday, January 18, 2024

To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.

Key Points: 
  • To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.
  • Helge brings to iXCells a wealth of entrepreneurial and intrapreneurial leadership experience across the life sciences and healthcare space in building businesses for small and large companies with a proven track record of value creation.
  • In addition, Dr. Bastian led oncology focused Indivumed and M2GEN (now Aster Insights) as Managing Director & Chief Commercial Officer and CEO, respectively.
  • Dr. Lynn Zhang will continue to serve on iXCells’ board of directors and assist with transitioning CEO leadership responsibilities in the coming months.

PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

Retrieved on: 
Wednesday, January 17, 2024

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.

Key Points: 
  • PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.
  • Members of the project consortium will receive €8.1M ($8.9M) in funding, including €4.7M ($5.1M) for PDC*line Pharma.
  • View the full release here: https://www.businesswire.com/news/home/20240117630349/en/
    The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
  • Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers , with a high recurrence rate post-surgery and chemotherapy.

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics

Retrieved on: 
Tuesday, January 23, 2024

OpCT-001 is the lead cell therapy candidate being developed under the strategic R&D collaboration between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics that was forged in 2021.

Key Points: 
  • OpCT-001 is the lead cell therapy candidate being developed under the strategic R&D collaboration between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics that was forged in 2021.
  • Under the terms of the agreement FUJIFILM Cellular Dynamics, and Opsis Therapeutics receive an undisclosed license fee and are eligible to receive payments upon achievement of certain development and commercial milestones.
  • "We believe that cell therapy has great potential for restoring vision in patients who are living with retinal diseases," said Ahmed Enayetallah, Senior Vice President and Head of Development at BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal disorders that includes retinitis pigmentosa and cone rod dystrophies.

Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, January 23, 2024

IRVING, Texas, Jan. 23, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • That's a major focus of the wide array of research Caris and our POA collaborators will proudly present at this year's ASCO GU."
  • The research is a collaboration with the Huntsman Cancer Institute at the University of Utah and other POA members.
  • Caris will present additional data from studies demonstrating the critical role of comprehensive molecular profiling in the treatment of genitourinary cancers.
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Pusan National University's Breakthrough in Muscle Regeneration: Nanotech Scaffolding Supports Tissue Growth

Retrieved on: 
Friday, January 19, 2024

To improve surgical outcomes, traditional muscle grafts are giving way to artificial scaffold materials, with MXene nanoparticles (NPs) standing out as a promising option.

Key Points: 
  • To improve surgical outcomes, traditional muscle grafts are giving way to artificial scaffold materials, with MXene nanoparticles (NPs) standing out as a promising option.
  • They are highly electrically conductive, can accommodate a wide range of functional groups, and have stacked structures that promote cell interactions and muscle growth.
  • They used DNA sequencing to reveal the genes and biological pathways activated by MXene NPs to aid in muscle regeneration.
  • "Within 5 to 10 years, this research may yield groundbreaking treatments for muscle injuries," Prof. Kim optimistically states.

Next-gen Sequencing and Genomic Analysis Advancements Report 2024 - Enabling Precision Medicine through High-precision Sequencing Approaches

Retrieved on: 
Thursday, January 18, 2024

DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Advancements in Next-gen Sequencing and Genomic Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 18, 2024 /PRNewswire/ -- The "Advancements in Next-gen Sequencing and Genomic Analysis" report has been added to ResearchAndMarkets.com's offering.
  • From Sanger sequencing to next-generation sequencing, technologies and chemistries have improved/advanced to reduce costs and ensure faster timelines.
  • Developments in NGS chemistries such as single-molecule real-time sequencing, sequencing by synthesis, nanopore sequencing, ion and semiconductor technology, in addition to miniaturization of sequencing instrumentation and automation of NGS, boost the adoption of NGS across biological labs.
  • Technological advancement of AI-/ML-powered platforms for analyzing sequencing data is helping analyze and interpret large volumes of sequencing data within hours.